The FDA's drug approvals database lists a supplement dated 6 October 2026 to NDA 218436 for remibrutinib, marketed as Rhapsido and held by Novartis. Remibrutinib is a Bruton tyrosine kinase inhibitor.
The record does not say what the supplement covers, and it does not say whether it concerns an oncology use. Nothing in it points to a safety communication or a new indication. For a prescriber, the entry is a prompt to read the current product information if you are considering the drug, not a reason to change practice. This is an FDA record only and says nothing about CDSCO status.
- The FDA entry lists a supplement; its content is not described in the record.
- The record does not state whether it concerns an oncology use.
- Read the current product information before relying on remembered prescribing details.
Why it matters
A supplement can be anything from paperwork to a labelling change, and the record does not say which.
Don't overread it
A supplement listed without detail is not a new indication or a safety warning.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free